| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Zhongxiong Peng CEO | XSHE Exchange | CNE100002102 ISIN |
| CN Country | 3,197 Employees | - Last Dividend | 26 May 2021 Last Split | - IPO Date |
Founded in 1992 and headquartered in Guangzhou, China, Guangzhou Wondfo Biotech Co., Ltd is a pioneering entity in the field of in vitro diagnostics. The company specializes in the development, manufacture, and distribution of point-of-care testing products along with solutions aimed at rapid diagnosis and the management of chronic diseases. By serving a pivotal role in clinical testing, emergency medicine, chronic disease management, primary care, epidemic response, disaster relief, on-site law enforcement, and family health management, Wondfo has made significant inroads in enhancing public health infrastructure on a global scale. Its international footprint extends to approximately 140 countries and regions, underlining its status as a major player in the global healthcare diagnostics industry.
Rapid Test Kits: These kits are designed for quick and efficient detection of various conditions, including COVID-19, drugs of abuse, tumors, infectious diseases, fertility issues, and sexually transmitted diseases. They embody the company's commitment to rapid diagnosis and are instrumental in immediate healthcare decision-making.
Immunofluorescence Devices: Wondfo's advanced devices are adept at detecting a range of critical health issues such as cardiovascular diseases, inflammation, kidney injuries, sex hormones abnormalities, thyroid function issues, diabetes, tumors, and more. These devices facilitate early diagnosis and proper disease management.
Blood Coagulation Analyzers: These analyzers are critical for assessing blood coagulation parameters, catering to patients with clotting disorders and monitoring anticoagulant therapy, thereby playing an essential role in preventing thrombotic events.
Optical Coagulation Analyzers: Employing optical methods, these analyzers offer another layer of precision in the examination of coagulation factors within the blood, essential for comprehensive hemostasis management.
Dry Chemistry Analyzers: These analyzers support a wide array of tests using dry chemistry technology, simplifying the process of chemical analysis and offering a robust solution for diagnostics away from laboratory settings.
Automatic Chemiluminescence Immunoassay Analyzers: With their high sensitivity and specificity, these analyzers play a critical role in the quantification of various biomarkers, aiding in the early detection and monitoring of numerous diseases.
Molecular Diagnostic Analyzers: These cutting-edge equipment cater to the burgeoning field of molecular diagnostics, offering solutions for genetic and infectious disease testing with high accuracy and efficiency, crucial for personalized medicine and targeted therapies.